Remove tag precision-public-health
article thumbnail

Grand Rounds December 15, 2023: Diversifying Clinical Trials: A Path Forward (Roxana Mehran, MD, FACC, FAHA, MSCAI, FESC)

Rethinking Clinical Trials

Diversity in clinical trials is important for generalizability of results, to provide equal opportunities, practice precision medicine, tailor practical guidelines, improve public health outcomes, detect potential differences in safety and efficacy, and to address health disparities. years for males and 5.5

article thumbnail

June 24, 2022: FDA Draft Guidance on Real-World Evidence (John Concato, MD, MS, MPH)

Rethinking Clinical Trials

Real-world data (RWD) is a term with specific regulatory implications referring to health care data routinely collected from a variety of sources. Terminology is important in research work, and we should strive to be as precise as possible with the terminology we use. and the FDA Draft Guidance for RWD/RWE. pctGR, @Collaboratory1.

Big Data 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds August 18, 2023: Opportunities to Improve Clinical Trials: Draft Revision of the ICH Good Clinical Practice Guideline (E6R3) (Prof Sir Martin Landray, FMedSci; M. Khair ElZarrad, PhD, MPH)

Rethinking Clinical Trials

Its objective is to improve efficiency of new drug development and registration processes, in addition to promoting public health, preventing duplication of clinical trial in humans and minimizing the use of animal testing without compromising safety and effectiveness. We see that as an important part of the future.

article thumbnail

Grand Rounds August 18, 2023: Opportunities to Improve Clinical Trials: Draft Revision of the ICH Good Clinical Practice Guideline (E6R3) (Prof Sir Martin Landray, FMedSci; M. Khair ElZarrad, PhD, MPH; Adrian F. Hernandez, MD, MHS)

Rethinking Clinical Trials

Its objective is to improve efficiency of new drug development and registration processes, in addition to promoting public health, preventing duplication of clinical trial in humans and minimizing the use of animal testing without compromising safety and effectiveness. We see that as an important part of the future.

article thumbnail

Revolutionizing Medicine and Public Health: The Emergence of Big Data in Healthcare

Roots Analysis

Velocity: Big Data needs to be handled promptly as businesses generate data at an unprecedented speed, driven by the growing adoption of Internet of Things (IoT), and technologies, such as RFID tags, sensors, and smart meters are used to deal with the high velocity of data in real-time. It is loosely arranged into categories using meta tags.

article thumbnail

New Rare Disease Drugs and Research Advancements

XTalks

Despite high price tags of a couple of million dollars, gene therapy makers say they are working to ensure patients are able to access the treatments through patient assistance programs developed in conjunction with the support of governments. Public-private partnerships are also playing a crucial role in advancing research and development.

article thumbnail

A roadmap for adopting New Science 

pharmaphorum

The pandemic’s disruption galvanised the biopharma industry into unprecedented action, demonstrating what’s possible when the global scientific community collaborates in exceptional ways and public-private partnerships drive innovation to address a common need. These will all help pay for New Science. .